Alaunos Says $350M Velaris Financing Restores Nasdaq Equity Compliance
TCRT has more than doubled off its 52-week low of $0.719 on light trading volume (0.3× avg).
Summary
Alaunos says the $350 million raised with the Velaris merger, plus Fairmount's waiver of a ~$9.0 million cash-settlement right, has restored compliance with Nasdaq's stockholders' equity requirement — pending Nasdaq confirmation and a November 10 hearing that is expected to be cancelled.
Key Events · Corporate Governance and Compliance · TCRT
-
Company Claims Nasdaq Equity Compliance Restored
Alaunos states that completion of the $350.0 million Financing, including the effect of the Waiver, has restored compliance with Nasdaq Listing Rule 5550(b)(1)'s $2,500,000 stockholders' equity requirement.
-
Fairmount Waives ~$9.0M Cash Settlement Right
Fairmount Fund II irrevocably waived the Cash Settlement Right on 6,268 Series C Preferred shares, valued at approximately $9.0 million, so conversion delivers common stock rather than cash until stockholder approval.
-
Delisting Hearing Set for November 10
The Nasdaq Hearings Panel hearing remains scheduled for November 10, 2026; the company expects it to be cancelled once Staff confirms regained compliance, with no assurance Nasdaq will concur.
-
Preferred Classification Depends on Stockholder Vote
Series B and non-waived Series C preferred will be classified outside permanent equity until stockholders approve conversion and the authorized-share increase; the Waived Shares and Financing common stock go into permanent equity.
Analysis · TCRT · Life Sciences
Alaunos was facing delisting after its equity fell below Nasdaq's $2.5 million minimum, with a hearing set for November 10. The $350 million raised alongside the Velaris merger — including Fairmount's waiver of the right to demand ~$9.0 million in cash on conversion of 6,268 Series C preferred shares — is what the company says cures the deficiency. That removes the immediate delisting overhang, but the fix depends on Nasdaq concurring and on stockholders later approving conversion of the Series B and Series C preferred and the related authorized-share increase; without that approval, the cash-settlement right revives for the non-waived preferred six months after issuance. The Q3 10-Q will still show the pre-transaction balance sheet, so reported equity will lag the actual fix.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 28.9% of the 1511 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRT was trading at $3.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9M. The 52-week trading range was $0.72 to $4.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.